Enveric Biosciences Inc vs Seagate Technology Holdings PLC — how do they compare? Enveric Biosciences Inc trades at $1.45 (market cap $6.20M), while Seagate Technology Holdings PLC trades at $830 (market cap $181.54B). The key difference: Seagate Technology Holdings PLC is far larger — about 29280.6× Enveric Biosciences Inc's market cap, and Seagate Technology Holdings PLC pays a 0.37% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | STX | |
|---|---|---|
Market Cap | $6.20M | $181.54B |
Sector | Health | Technology |
52-Week High | $17.40 | $1.09K |
52-Week Low | $1.27 | $154.43 |
Enterprise Value | $1.30M | $183.69B |
Dividend Yield | — | 0.37% |
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.55, down 0.64% with a bullish technical signal despite negative profitability. The company shows promising clinical progress with its lead candidate EB-003, supported by recent FDA guidance and positive preclinical data. While quarterly earnings consistently beat expectations, the company remains unprofitable with negative ROE and ROA. Analyst sentiment is positive with 75% buy ratings.
Investment outlook hinges on successful drug development milestones, with regulatory progress and intellectual property expansion providing catalysts. Key risks include clinical trial outcomes, cash burn from operations, and dependence on financing activities. The stock presents speculative growth potential for risk-tolerant investors focused on biotech innovation.
STX trades at $812.76, down 4.71% in the last 24 hours, with technical indicators showing a bearish trend and key support at $758. The company reported strong Q2 2026 earnings, beating estimates with EPS of $5.71 versus $5.10 expected, driven by AI storage demand. Valuation ratios are elevated, with a P/E of 58.47 and P/S of 15.26, while profitability remains robust with a net income margin of 26.11%.
Outlook is positive due to AI-driven growth and analyst consensus, but high valuation and competitive pressures pose risks. The consensus price target is $1,130, offering ~39% upside, supported by 28 buy ratings. Investors should weigh strong fundamentals against premium pricing and market volatility.
Trailing returns across standard periods
Latest headlines on both assets
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →Seagate is a leading supplier of hard disk drives for data storage to the enterprise and consumer markets. It forms a practical duopoly in the market with its chief rival, Western Digital
Read more on STX →